As weight-loss drugs are gaining popularity, a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everything investors need to know about this new weight-loss focused exchange-traded fund (ETF) before investing in OZEM stock below! OZEM ETF Details Roundhill GLP 1 & Weight Loss ETF has stakes in both Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). These are the makers of weight-loss drugs Ozempic, Wegovy and Moun ...

For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She'd tried five different programs in her life and never found lasting results. Her luck started to change last year, when she saw a promotion on Instagram for the Ro Body Program, a new offering from online health startup Ro. The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that's turned into a booming business in recent years. In this article Paten ...

Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Copenhagen, Denmark, 23 May 2024 – Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced topline results from the DREAM trial (Dapiglutide for the Treatment of Obesity), the investigat ...

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK, May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs. "OZEM ...

Formulations to be marketed as "Slim" and "Trim" as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide ("Slim") and Tirzepatide ("Trim") to ...

Nestle is launching a new frozen-food brand, Vital Pursuit, aimed at the growing market of consumers who are using GLP-1 drugs like Ozempic and Wegovy. Nestle already owns Lean Cuisine, which was founded in 1981 as a healthier alternative to other frozen meals. But the company chose to create a new brand to reach GLP-1 users because Lean's branding focuses on consumers looking to limit their calories. But people who take GLP-1 medications may want to consume more nutrients, like protein, which can help with ...

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. About this content About William Farrington William kickstarted hi ...

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday. The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage. GLP-1s work by mimicking a hormone produced in the gut to tamp down a person's appetite and regulate their blood sugar. When those medications are in shortage, cert ...

Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein (LDL) cholesterol (both, p<0.0001) compared to placebo two months after administration New results highlight potential for profound, durable, and broad metabolic benefit that can be achieved from single-admi ...

Could Amgen be the next stock to soar due to a GLP-1 drug? Glucagon-like peptide 1 (GLP-1) weight-loss drugs such as Zepbound and Wegovy are growing in popularity. And that has made the companies who make those drugs, Eli Lilly and Novo Nordisk, hot investments over the past few years. But there could soon be many more options out there for patients. Given the potential for a weight-loss drug to generate tens of billions of dollars in revenue for a company, there's bound to be a lot of interest in the space ...